Friedrich Graf Finckenstein

Friedrich Graf Finckenstein

Company: Iovance Biotherapeutics

Job title: Chief Medical Officer


Clinical Success of the TIL Technology Platform in Solid Tumors 1:30 pm

Highlight advantages of polyclonal TIL MOA for solid tumors Improving access to TIL using a proprietary, scalable, commerciallyviable manufacturing process Review positive clinical data for TIL in metastatic melanoma and other solid tumor types Explore next-generation approachesRead more

day: Conference Day 1

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.